A Pre-Approval Information Exchange (PIE) Webinar, presented by Karuna Therapeutics.

Despite multiple treatment options, managing schizophrenia remains challenging. A significant unmet need exists for antipsychotics with broader efficacy and better tolerability. Recognized by Fierce Pharma as the most anticipated launch of 2024, KarXT has the potential to be a completely new and differentiated treatment for people with schizophrenia.

This webinar is only offered to payers, formulary committees, or other similar entities responsible for the selection of drugs for coverage or reimbursement. In order to join this webinar, you must be registered as a user of FormularyDecisions^®.

This product is in the clinical evaluation stage and has not been approved for use by the FDA. The safety and efficacy of this product have not been established.

A Science & Innovation Webinar, presented by Abbvie.

Inflammatory Bowel Disease (IBD) is a chronic, unpredictable, inflammatory disorder of the digestive tract with major clinical and economic burden. The American Gastroenterological Association Guidelines and the STRIDE-II Recommendations include long-term goals for the management of IBD, with a focus on long-term patient outcomes. The objective of this webinar is to review IBD, treatment guidelines and professional recommendations, clinical decision making and the associated economic burden.

A Pre-Approval Information Exchange (PIE) Webinar sponsored by Servier.

Servier, a global pharmaceutical group, is excited to provide an overview of vorasidenib, an investigational treatment for patients with mIDH glioma. As the potential first-in-class targeted therapy for mIDH glioma, vorasidenib was granted fast track designation by the FDA, with an anticipated PDUFA date in Q3 2024. This webinar will provide an overview of mIDH glioma and highlight the clinical information of vorasidenib.

This webinar is only offered to payers, formulary committees, or other similar entities responsible for the selection of drugs for coverage or reimbursement. In order to join this webinar, you must be registered as a user of FormularyDecisions^®.

This product is in the clinical evaluation stage and has not been approved for use by the FDA. The safety and efficacy of this product have not been established.

A Pre-Approval Information Exchange (PIE) Webinar, sponsored by Elevar Therapeutics.

You are invited to attend a virtual PIE Webinar about a new investigational treatment for unresectable or metastatic hepatocellular carcinoma (uHCC): Rivoceranib + Camrelizumab.

This webinar is only offered to payers, formulary committees, or other similar entities responsible for the selection of drugs for coverage or reimbursement. In order to join this webinar, you must be registered as a user of FormularyDecisions^®.

This product is in the clinical evaluation stage and has not been approved for use by the FDA. The safety and efficacy of this product have not been established.

As new therapeutic options emerge for managing food allergies, managed care organizations face the crucial task of evaluating their clinical efficacy and safety profiles to formulate coverage policies. Considering the potential for new therapeutics to reduce emergency room visits and enhance patents' quality of life, it is essential to assess the cost implications comprehensively.

Join us for this webinar as we delve into these critical considerations and explore strategies to accommodate innovative treatments in managed care.

A Science & Innovation Webinar, sponsored by Boehringer Ingelheim.

Validated tools are needed to estimate the risk of the more than 35 million adults living with chronic kidney disease (CKD). Boehringer Ingelheim and Carelon Research have conducted the first large-scale US validation of a new AI-driven tool for chronic kidney disease. This program will discuss the Klinrisk AI model's capability to predict disease progression in individuals at all stages of CKD.

An AMCP Webinar, hosted by FormularyDecisions^®.

Join us for an interactive, engaging, and informative discussion as we dive into the evolving landscape of pre-approval information exchange (PIE). Our diverse panel of biopharma and market access and communication experts will guide you through a live session filled with valuable insights and strategies for engaging healthcare decisionmakers with pre-approval information. We will explore opportunities and innovative solutions for leveraging PIE when collaborating with stakeholders.

Cencora thought leaders will be sharing their expertise on how to navigate complex terrain and discover new opportunities for success with up-to-date insights on industry trends. Don't miss out - register today to secure your spot!

A Pre-Approval Information Exchange (PIE) Webinar, sponsored by Moderna.

mRNA-1345, is an investigational vaccine from Moderna US, Inc. for the prevention of lower respiratory tract disease and acute respiratory disease caused by RSV in adults 60 years of age and older. This webinar will review the mechanism of action as well as Phase 3 clinical trial data for mRNA-1345. mRNA-1345 is currently under review by the US FDA.  The product or use is not approved/cleared/licensed, and the safety or effectiveness of the product or use has not been established.

This webinar is only offered to payers, formulary committees, or other similar entities responsible for the selection of drugs for coverage or reimbursement. In order to join this webinar, you must be registered as a user of FormularyDecisions^®.

This product is in the clinical evaluation stage and has not been approved for use by the FDA. The safety and efficacy of this product have not been established.